Plain-English translation of NCT06561152 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach for people with acute myeloid leukemia—a serious blood cancer—that has come back or stopped responding to standard initial therapy. The study combines three medications: (a newer drug designed to target leukemia cells), plus two chemotherapy drugs given at lower doses than traditional chemotherapy. Researchers want to find the safest and most effective dose of this combination.
Many people with this type of blood cancer eventually stop responding to the first-line treatments that doctors typically use. This medication is designed to work differently than standard chemotherapy, targeting specific features of the cancer cells, and researchers hope that combining it with low-dose chemotherapy may help people for whom initial treatments have failed.
You likely qualify if…
You likely don't qualify if…
In this trial, you would receive the three medications through IV infusions over a series of days during each treatment cycle. The study starts with lower doses and may gradually increase them depending on how well you tolerate the treatment and how you respond. You will have regular blood tests, heart monitoring (ECG), and clinic visits to check your health and how the cancer is responding. The exact schedule of visits and how long you participate will depend on how your body responds to treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Stanford University
Collaborators
Stemline Therapeutics, Inc.
Enrollment target
~20 participants
Started
February 2025
Primary completion
October 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Woo In (Yustina) Cho
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.